<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Protalix BioTherapeutics Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/protalix-biotherapeutics-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PLX) Protalix BioTherapeutics Sees FDA Setback for Gaucher Drug</title>
		<link>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728</link>
		<comments>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728#comments</comments>
		<pubDate>Sat, 05 Mar 2011 00:49:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67728</guid>
		<description><![CDATA[Protalix BioTherapeutics, Inc. (PLX) was dealt a huge blow recently with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for the company’s Gaucher disease candidate, taliglucerase alfa. FDA Requests Additional Information The FDA asked the company to provide additional information related to clinical and chemistry, manufacturing and controls (CMC). While the agency did not ask the company to conduct additional studies, it asked Protalix to provide data from the company’s switchover and long-term extension trials. Besides this, the FDA asked the company to submit information on testing specifications and assay validation. Depending on specific requirements, the Gaucher disease candidate&#8217;s approval could get delayed by a year. The first-round approval of taliglucerase alfa would have been a major boost for Protalix, which has a strong marketing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Protalix BioTherapeutics Seek EU Approval</title>
		<link>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746</link>
		<comments>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746#comments</comments>
		<pubDate>Tue, 21 Dec 2010 21:25:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60746</guid>
		<description><![CDATA[Pfizer (PFE) and its partner Protalix BioTherapeutics Inc. (PLX) recently announced that they have submitted the Marketing Authorization Application (MAA) for their Gaucher disease candidate in the EU. The companies are seeking marketing approval for Uplyso (taliglucerase alfa) from the European Medicines Agency. Uplyso is currently under regulatory review in the US with a response from the Food and Drug Administration (FDA) expected by Feb 25, 2011. Uplyso enjoys orphan drug status in both the EU and the US for the Gaucher disease indication. The approval of Uplyso will be a major boost for Protalix which has a strong marketing partner in Pfizer. The companies entered into a commercialization agreement in late 2009. Per the terms of the agreement, Pfizer has exclusive worldwide rights for the commercialization of Uplyso in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Makes Hostile Bid for Genzyme</title>
		<link>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301</link>
		<comments>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301#comments</comments>
		<pubDate>Mon, 11 Oct 2010 15:29:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54301</guid>
		<description><![CDATA[French pharma giant Sanofi-Aventis (SNY) recently went hostile with its bid to acquire biotech company Genzyme Corporation (GENZ). Sanofi has launched a tender offer for all outstanding shares of Genzyme – the offer is scheduled to expire on Dec 10. Sanofi’s offer price stands at $69 per share with the entire deal being valued at $18.5 billion. The $69 offer price represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up more than 40%. Sanofi said that it launched the hostile bid mainly due to Genzyme management’s refusal to enter into constructive discussions with Sanofi. Sanofi had initially approached Genzyme with its $69 per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Rejects Sanofi-Aventis’ Aquisition Offer</title>
		<link>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857</link>
		<comments>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:25:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49857</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently rejected Sanofi-Aventis’ (SNY) offer to acquire the company for $69 per share. Earlier in the day, Sanofi had announced its non-binding proposal to Genzyme with the all-cash transaction being valued at $18.5 billion. However, Genzyme’s board of directors rejected the offer calling it unrealistic. According to Genzyme, the offer price undervalues the company. The offer price of $69 per share represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up 35.6%. What Does Sanofi Gain? Sanofi has a high exposure to generic risk on many of its leading franchises. The company suffered a blow recently with the entry of a generic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PLX) Protalix Biotherarapeutics &#8211; Added to Barchart Van Meerten Speculative Portfolio</title>
		<link>http://www.stockbloghub.com/2010/09/04/plx-protalix-biotherarapeutics-added-to-barchart-van-meerten-speculative-portfolio/50289</link>
		<comments>http://www.stockbloghub.com/2010/09/04/plx-protalix-biotherarapeutics-added-to-barchart-van-meerten-speculative-portfolio/50289#comments</comments>
		<pubDate>Sat, 04 Sep 2010 15:40:09 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50289</guid>
		<description><![CDATA[Protalix Biotherapeutics (PLX) was added to the Barchart Van Meerten Speculative portfolio this morning. They are engaged in the provision of practice management services to the Affiliated Practices pursuant to long-term Administrative Services Agreements with separately organized affiliated professional associations. Under the Administrative Services Agreements, they have control over all non-orthodontic functions of the PA Contractors Incorporatedluding administrative, management, billing and support functions. Dentists have a reputation of being poor business managers, so they need all the help they can get. The fundamentals of this stock are very hard to believe. Seven Wall Street brokerage firms have buy recommendations published based on their consensus estimates that sales will increase 1647.40% this year and 542.00% next year. Please &#8211; these are their estimates not mine. They believe earnings will increase 26.80% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/04/plx-protalix-biotherarapeutics-added-to-barchart-van-meerten-speculative-portfolio/50289/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Plc Earns European Approval for Vpriv</title>
		<link>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588</link>
		<comments>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588#comments</comments>
		<pubDate>Sun, 29 Aug 2010 03:33:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49588</guid>
		<description><![CDATA[Recently, Shire Plc. (SHPGY) received a boost when the European Commission approved its Gaucher disease product Vpriv (velaglucerase alfa) for marketing in 30 European countries. The decision to approve the product does not come as a surprise as the drug’s approval for the long-term treatment of type I Gaucher disease was recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in June 2010. Vpriv, an enzyme replacement therapy, enjoys orphan drug status from the Committee for Orphan Medical Products. Vpriv is already available in the US where it received approval from the US Food and Drug Administration in March 2010. Gaucher disease, a genetically transmitted disease, has an incidence of approximately 1 in a population of 50,000. The disorder mainly leads to the enlargement ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Second Quarter 2010 Earnings Miss by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257</link>
		<comments>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257#comments</comments>
		<pubDate>Thu, 22 Jul 2010 02:02:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44257</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported second quarter earnings of 6 cents per share (excluding one-time items but including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of 36 cents and the year-earlier earnings of 64 cents. Excluding the impact of stock-based compensation expense, earnings came in at 18 cents. With the company yet to emerge from manufacturing problems, we were not surprised to see the dismal second quarter results. Second quarter revenues declined 12% to $1.08 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Genzyme’s Personalized Genetic Health business was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The Personalized Genetic Health segment posted sales of $350.5 million, down 40%. Production and supply of two products, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire plc Hears Good News From European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791</link>
		<comments>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791#comments</comments>
		<pubDate>Sun, 11 Jul 2010 14:23:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41791</guid>
		<description><![CDATA[Recently Shire plc (SHPGY) announced that its Gaucher disease product VPRIV (velaglucerase alfa) has received a favorable opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The committee recommended the approval of the enzyme replacement therapy for treating type I Gaucher disease. Furthermore, the drug has been granted accelerated assessment by the EMA in the European Union (EU) and enjoys orphan drug status from the Committee for Orphan Medical Products. Shire should be in a position to launch Vpriv in the EU by year end. Meanwhile, product launch in other countries should commence in 2011. Vpriv is already available in the U.S. where it received approval from the U.S. Food and Drug Administration (FDA) in late February 2010. Vpriv Could Eat into Cerezyme’s Market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218</link>
		<comments>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218#comments</comments>
		<pubDate>Tue, 25 May 2010 03:53:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38218</guid>
		<description><![CDATA[Following the release of first quarter results on April 21, 2010, several analysts covering Genzyme Corporation (GENZ) have lowered their earnings estimates for 2010 and 2011. Genzyme is still suffering from the impact of the temporary shutdown of its Allston Landing manufacturing facility last year and has yet to resume normal supply of the key products that were affected by the shutdown. First Quarter Highlights Genzyme reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents. With the company facing manufacturing problems from mid-2009, we were not surprised to see first quarter revenues decline 6.5% to $1.07 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Agreement of Analysts Following the release of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme First Quarter Earnings Beat by a Penny</title>
		<link>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621</link>
		<comments>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621#comments</comments>
		<pubDate>Thu, 22 Apr 2010 19:57:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34621</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents. With the company facing manufacturing problems from mid-2009, we were not surprised to see first quarter revenues decline. They fell 6.5% to $1.07 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Genzyme’s Personalized Genetic Health business (previously referred to as the Genetic Diseases business) was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The Personalized Genetic Health segment posted sales of $392.5 million, down 29%. Production and supply of two products, Cerezyme and Fabrazyme, were mainly affected by the temporary shutdown. While Cerezyme sales declined 39% to $179 million, Fabrazyme ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Presents Positive Data on Vpriv</title>
		<link>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189</link>
		<comments>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:09:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32189</guid>
		<description><![CDATA[Shire Plc. (SHPGY) recently presented positive phase III data on its Gaucher disease product, Vpriv. The trial was conducted to study the safety of switching patients from Genzyme’s (GENZ) Cerezyme (imiglucerase) to Vpriv. Results showed that both adult as well as pediatric patients who switched from Cerezyme to Vpriv did not develop IgG antibodies to Vpriv. This included 3 patients who tested positive for anti-Cerezyme antibodies at screening. Moreover, it was found that hemoglobin concentration, platelet counts, and liver and spleen volumes remained stable during the one year study, showing safety and maintenance of efficacy during this period. Shire also presented interim safety data from an ongoing multi-center open-label treatment protocol, which was put in place to provide Vpriv to patients affected by the shortage in supply of Cerezyme. Meanwhile, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Sees FDA Consent Decree Likely</title>
		<link>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996</link>
		<comments>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996#comments</comments>
		<pubDate>Sat, 27 Mar 2010 20:43:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31996</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period, it would also require Genzyme to make payments to the government and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Likely to See FDA Enforcement Action</title>
		<link>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768</link>
		<comments>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768#comments</comments>
		<pubDate>Thu, 25 Mar 2010 19:53:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31768</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period of time, it would also require Genzyme to make payments to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Hospira Inks Manufacturing Deal with Genzyme</title>
		<link>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213</link>
		<comments>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213#comments</comments>
		<pubDate>Tue, 05 Jan 2010 22:25:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24213</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) has entered into a contract manufacturing agreement with Hospira (HSP) for its key drugs Incorporatedluding Cerezyme and Fabrazyme. We believe this move has been taken to reduce the impact of the company’s manufacturing plant-related issues on the supply of its products. Any financial detail of the deal, which is set to expire in 2015, has not been disclosed. The deal has yet to receive regulatory approval for the manufacturing of these drugs. Genzyme has been under significant pressure following the shutdown of its Allston manufacturing facility in June 2009. The shutdown is a major setback as three drugs Incorporatedluding Cerezyme, were being manufactured at the facility. The closure of the plant has affected Genzyme’s financial performance significantly with third quarter revenues declining 9% to $1.06 billion. Last ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PLX) Protalix Biotherapeutics&#8217; Drug Advances</title>
		<link>http://www.stockbloghub.com/2009/12/11/plx-protalix-biotherapeutics-drug-advances/22576</link>
		<comments>http://www.stockbloghub.com/2009/12/11/plx-protalix-biotherapeutics-drug-advances/22576#comments</comments>
		<pubDate>Fri, 11 Dec 2009 13:35:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22576</guid>
		<description><![CDATA[Good news for Protalix Biotherapeutics (PLX) once again! The company completed the submission of its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for taliglucerase alfa, which is meant for the treatment of Gaucher disease. It has been granted orphan-drug designation and fast-track status by the FDA to facilitate its development. Taliglucerase alfa is currently being given to patients suffering from Gaucher disease in the US and the European Union under the Expanded Access Program and compassionate use protocol, respectively. Earlier this month, the company entered into an agreement with Pfizer (PFE) related to the development and commercialization of this drug. As per the deal, Pfizer will have exclusive worldwide licensing rights to commercialize taliglucerase alfa while Protalix has retained its commercialization rights in Israel. Under ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/plx-protalix-biotherapeutics-drug-advances/22576/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Resumes Cerezyme Shipment</title>
		<link>http://www.stockbloghub.com/2009/12/03/genz-genzyme-resumes-cerezyme-shipment/21850</link>
		<comments>http://www.stockbloghub.com/2009/12/03/genz-genzyme-resumes-cerezyme-shipment/21850#comments</comments>
		<pubDate>Thu, 03 Dec 2009 22:45:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21850</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently reported progress on the resumption of supply of new lots of Cerezyme from its Allston Landing manufacturing facility, which was temporarily shut down due to contamination issues. The company announced that it has started shipping vials of the newly produced Cerezyme. The initial lot of the Cerezyme shipment will be used to provide uninterrupted treatment to the most vulnerable patients. By the end of Dec, the company expects to expand supply so as to cover those patients who had experienced interruptions in treatment due to the shortage in supply. Genzyme believes it will be able to meet worldwide demand for the product in the first quarter of 2010. Genzyme also provided an update on the resumption of supply of Fabrazyme, indicated for Fabry disease, which was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/03/genz-genzyme-resumes-cerezyme-shipment/21850/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Plc&#8217;s Drug Seeks European Medicines Agency Approval</title>
		<link>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289</link>
		<comments>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:10:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21289</guid>
		<description><![CDATA[Shire plc (SHPGY) continues to make progress with its Gaucher disease candidate, velaglucerase alfa. The company recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for velaglucerase alfa for the treatment of type I Gaucher disease. The company has already asked for approval in other markets like the U.S. and Canada. Shire is seeking an accelerated review of the MAA. Given the shortage in supply of Genzyme’s (GENZ) Cerezyme, which is the leader in the treatment of patients with Gaucher disease, the Committee for Medicinal Products for Human Use (CHMP) has accepted Shire’s request. Accordingly, the review time has been reduced by 60 days to 150 days with the review scheduled to commence in December. Once approved and launched commercially, velaglucerase alfa will compete directly with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corp Haunted by Contamination Issues</title>
		<link>http://www.stockbloghub.com/2009/11/16/genz-genzyme-corp-haunted-by-contamination-issues/20699</link>
		<comments>http://www.stockbloghub.com/2009/11/16/genz-genzyme-corp-haunted-by-contamination-issues/20699#comments</comments>
		<pubDate>Tue, 17 Nov 2009 01:03:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20699</guid>
		<description><![CDATA[Biotech company Genzyme Corp. (GENZ), faced yet another setback recently when the U.S. Food and Drug Administration (FDA) announced that vials of five drugs marketed by the company were found to be contaminated. The affected drugs include Cerezyme, Myozyme, Fabrazyme, Aldurazyme and Thyrogen. All these drugs, excluding Thyrogen, are indicated for the treatment of rare disorders. The vials were found to be contaminated with stainless steel fragments, non-latex rubber from the vial stopper, and fiber-like material from the manufacturing process which could potentially harm patients. As adverse events are yet to be reported and given the lack of alternative treatments for these drugs which treat rare disorders, the FDA did not issue a product recall. Instead, Genzyme has issued letters to U.S. healthcare providers reminding them to conduct a visual ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/16/genz-genzyme-corp-haunted-by-contamination-issues/20699/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Misses &amp; Slashes Earnings Guidance Again for 2009</title>
		<link>http://www.stockbloghub.com/2009/10/21/genz-genzyme-misses-slashes-earnings-guidance-again-for-2009/18392</link>
		<comments>http://www.stockbloghub.com/2009/10/21/genz-genzyme-misses-slashes-earnings-guidance-again-for-2009/18392#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:07:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18392</guid>
		<description><![CDATA[This morning, Genzyme Corp (GENZ) reported third quarter earnings of 19 cents per share, which was well below the Zacks Consensus Estimate of 31 cents and the year ago earnings of 93 cents. Moreover, revenues declined 9% to $1.06 billion. As expected, the temporary shutdown of the company’s Allston manufacturing facility earlier this year impacted overall financial results. Although the company has resumed production at this facility, the temporary shutdown led to a disruption in the supply of key products Cerezyme and Fabrazyme. Cerezyme’s performance was highly affected with sales dropping 69.7% to $93.6 million in the reported quarter. Fabrazyme sales came in at $115.2 million, down 8% from the prior-year quarter. Genzyme expects to resume supply of new lots of Cerezyme and Fabrazyme from late November and late December, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/genz-genzyme-misses-slashes-earnings-guidance-again-for-2009/18392/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Struggles to Restore Order</title>
		<link>http://www.stockbloghub.com/2009/09/26/genz-genzyme-struggles-to-restore-order/16092</link>
		<comments>http://www.stockbloghub.com/2009/09/26/genz-genzyme-struggles-to-restore-order/16092#comments</comments>
		<pubDate>Sat, 26 Sep 2009 21:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16092</guid>
		<description><![CDATA[On Wednesday, Genzyme Corp. (GENZ) provided a mixed update on its supply schedule for Cerezyme and Fabrazyme. The two key contributors to the company’s top line are produced at its Allston plant. Last June, Genzyme had to temporarily shut down this unit due to contamination issues. While we were pleased to hear that Cerezyme production is on track and new batches of the product will be available for shipment in the November-December timeframe, we were disappointed to hear that new lots of Fabrazyme will not be available for shipment till mid-December. Moreover, the volume of finished products of Fabrazyme will be lower than expected. The company said that Fabrazyme bioreactors were restarted later than planned and output from the two bioreactors is expected to be lower. We believe the delay ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/26/genz-genzyme-struggles-to-restore-order/16092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

